The Impact of Sorafenib on Phospho-FLT3 Inhibition and FLT3-ITD MRD after Chemotherapy: Correlative Studies from the Phase 2 Randomized Study of Sorafenib Versus Placebo in Combination with Intensive Chemotherapy in Previously Untreated Patients with FLT3-ITD Acute Myeloid Leukemia (ALLG AMLM16)

MLA

Michael Murray, et al. “The Impact of Sorafenib on Phospho-FLT3 Inhibition and FLT3-ITD MRD after Chemotherapy: Correlative Studies from the Phase 2 Randomized Study of Sorafenib Versus Placebo in Combination with Intensive Chemotherapy in Previously Untreated Patients with FLT3-ITD Acute Myeloid Leukemia (ALLG AMLM16).” Blood, vol. 136, Nov. 2020, pp. 16–18. EBSCOhost, https://doi.org/10.1182/blood-2020-141711.

APA

Michael Murray, Paula Marlton, Andrew Grigg, Andrew W. Roberts, Sarah MacRaild, Tristan Rawling, James D’Rozario, Giovanna Pomilio, Adam Ivey, Anthony P. Schwarer, Glen A Kennedy, Mark J. Levis, Doen Ming Ong, Anoop K Enjeti, Ian Bilmon, Andrew H. Wei, & Natasha S Anstee. (2020). The Impact of Sorafenib on Phospho-FLT3 Inhibition and FLT3-ITD MRD after Chemotherapy: Correlative Studies from the Phase 2 Randomized Study of Sorafenib Versus Placebo in Combination with Intensive Chemotherapy in Previously Untreated Patients with FLT3-ITD Acute Myeloid Leukemia (ALLG AMLM16). Blood, 136, 16–18. https://doi.org/10.1182/blood-2020-141711

Chicago

Michael Murray, Paula Marlton, Andrew Grigg, Andrew W. Roberts, Sarah MacRaild, Tristan Rawling, James D’Rozario, et al. 2020. “The Impact of Sorafenib on Phospho-FLT3 Inhibition and FLT3-ITD MRD after Chemotherapy: Correlative Studies from the Phase 2 Randomized Study of Sorafenib Versus Placebo in Combination with Intensive Chemotherapy in Previously Untreated Patients with FLT3-ITD Acute Myeloid Leukemia (ALLG AMLM16).” Blood 136 (November): 16–18. doi:10.1182/blood-2020-141711.